Ancilia Biosciences

Executive Summary

Ancilia Biosciences, founded in 2021 and headquartered in Cambridge, Massachusetts, is pioneering a novel approach to microbiome therapeutics by applying CRISPR technology to protect beneficial bacteria from bacteriophages. The company’s proprietary platforms engineer live biotherapeutics and other bacterial products to resist viral destruction, potentially unlocking the full therapeutic potential of the microbiome. By addressing the critical challenge of phage susceptibility, Ancilia aims to enhance the stability and efficacy of microbiome-based treatments for a range of diseases. The company operates at the intersection of the microbiome and virome, leveraging CRISPR-mediated viral immunity to create robust bacterial strains that can survive in complex environments, including the human gut. This technology could transform the development of live biotherapeutics, making them more durable and effective, and expand the scope of microbiome interventions. Currently, Ancilia is in the early stages of platform development and is actively seeking partners and funding to advance its technology toward preclinical validation.

Upcoming Catalysts (preview)

• Q1 2027Series A financing round60% success
• Q3 2026Publication of proof-of-concept data in a peer-reviewed journal70% success
• TBDStrategic collaboration with a larger microbiome or biotech company40% success